iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

GSK, iTeos TIGIT drug belrestotug shows efficacy in PD-L1-high NSCLC trial at ESMO, giving some positive news for the beleaguered class.

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

SOMERVILLE, Mass., July 01, 2025--bluebird bio ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the appointment of Brian Riley as President and Chief Technical ...

Brian Riley as President and Chief Technical Officer, Joanne Lager, MD as Chief Medical Officer, and Adrian Chaisson as Chief of Staff.

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

Read about ITeos Therapeutics Inc Ordinary Shares (ITOS:XNAS) stock and today's latest news and financial updates.

Democratic U.S. Senator Maggie Hassan has reportedly launched an investigation into British pharmaceutical giant GSK's (NYSE:GSK) decision to pull the branded Flovent HFA asthma inhaler from the U ...